Top

Osteoporosis International

Published in:

01-05-2014 | Original Article

Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005–2008: Is treatment with bisphosphonates an option?

Authors: R. Lubwama, A. Nguyen, A. Modi, C. Diana, P. D. Miller

Published in: Osteoporosis International | Issue 5/2014

Abstract

Summary

Bisphosphonates are the first-line treatment for osteoporotic (OP) women; however, therapy is not recommended in severe renal impairment (RI). This study examined RI prevalence among OP women. Nearly a quarter of women had moderate RI, and 3.59 % would not be recommended for bisphosphonates, demonstrating a need for better therapeutic alternatives.

Introduction

Bisphosphonates are the recommended first-line treatment for postmenopausal women with OP. However, bisphosphonates are cleared through the kidney, and therapy is not recommended in severe RI due to adverse treatment effects observed with intravenous formulations. The objective of this study was to examine the prevalence of RI among women with OP aged ≥50 years in the USA.

Methods

Women with OP aged ≥50 years were identified using the 2005–2008 National Health and Nutrition Examination Survey (NHANES) data. OP was defined as prior OP diagnosis, previous hip or spine fracture, or measured lumbar spine/femoral neck bone mineral density (BMD) T-score <−2.5. The 2005 Modification of Diet in Renal Disease (MDRD) formula was used to calculate the glomerular filtration rate (GFR). Moderate and severe RI was defined as GFR 30–59 and 15–29 mL/min, respectively. Bisphosphonate therapy was considered not recommended among women with OP if GFR was <35 mL/min.

Results

The prevalence of OP among women in USA aged ≥50 years was 27 % (12.7 million). Nearly a quarter of women with OP (23.54 ± 2.02 %; 2.9 million) had moderate RI and 1.88 ± 0.28 % (230,000) had severe RI. Correspondingly, bisphosphonate therapy would not be recommended for an estimated 439,000 women with OP (3.59 ± 0.73 %).

Conclusions

Nearly a quarter of postmenopausal women with OP have moderate RI, and over 3 % would not be recommended for bisphosphonate treatment. These data reveal a need for better therapeutic alternatives that can be used in this patient population.

Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ III (2012) The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008. Osteoporos Int 23(3):811–820. doi:10.1007/s00198-011-1694-y PubMedCrossRef

Looker AC, Melton LJ III, Harris TB, Borrud LG, Shepherd JA (2010) Prevalence and trends in low femur bone density among older US adults: NHANES 2005–2006 compared with NHANES III. J Bone Miner Res 25(1):64–71. doi:10.1359/jbmr.090706 PubMedCrossRefPubMedCentral

Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286(22):2815–2822PubMedCrossRef

Langsetmo L, Goltzman D, Kovacs CS, Adachi JD, Hanley DA, Kreiger N, Josse R, Papaioannou A, Olszynski WP, Jamal SA (2009) Repeat low-trauma fractures occur frequently among men and women who have osteopenic BMD. J Bone Miner Res 24(9):1515–1522. doi:10.1359/jbmr.090319 PubMedCrossRef

National Osteoporosis Foundation (2010) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, http://www.nof.org/files/nof/public/content/file/344/upload/159.pdf. Accessed 12 Feb 2013

Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118–4124PubMedCrossRef

Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G (2002) Meta-analysis of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23(4):517–523PubMedCrossRef

Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350(12):1189–1199. doi:10.1056/NEJMoa030897 PubMedCrossRef

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822. doi:10.1056/NEJMoa067312 PubMedCrossRef

10.

Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809. doi:10.1056/NEJMoa074941 PubMedCrossRef

11.

Green JR, Seltenmeyer Y, Jaeggi KA, Widler L (1997) Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 80(5):225–230PubMedCrossRef

12.

Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97(7):2272–2282. doi:10.1210/jc.2012-1027 PubMedCrossRef

13.

Miller PD (2011) The kidney and bisphosphonates. Bone 49(1):77–81. doi:10.1016/j.bone.2010.12.024 PubMedCrossRef

14.

Sadowski CA, Spencer T, Yuksel N (2011) Use of oral bisphosphonates by older adults with fractures and impaired renal function. Can J Hosp Pharm 64(1):36–41PubMedPubMedCentral

15.

(2012) Fosamax [package insert]. Whitehouse Station, NJ: Merck and Co., Inc.

16.

Federal Food and Drug Administration (FDA) (2011) FDA Drug Safety Communication: new contraindication and updated warning on kidney impairment for Reclast (zoledronic acid). U.S. Food and Drug Administration, Department of Health and Human Services, Silver Spring, http://www.fda.gov/Drugs/DrugSafety/ucm270199.htm. Accessed 15 May 2012

17.

(2011) Boniva [package insert]. San Francisco, CA: Genentech, Inc.

18.

(2012) Actonel [package insert]. North Norwich, NY: Norwich Pharmaceuticals, Inc.

19.

Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2009) National Health and Nutrition Examination Survey (NHANES) 2007–2008 Public Data General Release File Documentation. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/generaldoc_e.htm. Accessed: May 8, 2012

20.

Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2005) National Health and Nutrition Examination Survey (NHANES) 2005–2006 Public Data General Release File Documentation. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/data/nhanes/nhanes_05_06/general_data_release_doc_05_06.pdf. Accessed: May 8, 2012

21.

Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2009) National Health and Nutrition Examination Survey (NHANES): 2005–2006 Data documentation, codebook, and frequencies: dual-energy X-ray absorptiometry—femur bone measurements. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/DXXFEM_D.htm. Accessed 8 May 2012

22.

Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2009) National Health and Nutrition Examination Survey (NHANES): 2007–2008 Data documentation, codebook, and frequencies: dual-energy X-ray absorptiometry—femur. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/DXXFEM_E.htm Accessed 8 May 2012

23.

Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2010) National Health and Nutrition Examination Survey (NHANES): 2005–2006 Data documentation, codebook, and frequencies: dual-energy X-ray absorptiometry—spine. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/DXXSPN_D.htm. Accessed 8 May 2012

24.

Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2010) National Health and Nutrition Examination Survey (NHANES): 2007–2008 Data documentation, codebook, and frequencies: dual-energy X-ray absorptiometry—spine. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/DXXSPN_E.htm. Accessed 8 May 2012

25.

Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP (1997) Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12(11):1761–1768. doi:10.1359/jbmr.1997.12.11.1761 PubMedCrossRef

26.

Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8(5):468–489PubMedCrossRef

27.

Kelly TJ (1990) Bone mineral density reference databases for American men and women. J Bone Miner Res 5(Suppl 1):S249

28.

Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2009) National Health and Nutrition Examination Survey (NHANES): 2007–2008 Data documentation, codebook, and frequencies: urinary albumin and urinary creatinine. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2007–2008/ALB_CR_E.htm Accessed 15 May 2012

29.

Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2007) National Health and Nutrition Examination Survey (NHANES): 2005–2006 Data documentation, codebook, and frequencies: urinary albumin and urinary creatinine. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2005–2006/ALB_CR_D.htm Accessed 15 May 2012

30.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612PubMedCrossRefPubMedCentral

31.

Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139(2):137–147PubMedCrossRef

32.

National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2 Suppl 1):S1-266

33.

Thorp ML, Eastman L, Smith DH, Johnson ES (2006) Managing the burden of chronic kidney disease. Dis Manag 9(2):115–121. doi:10.1089/dis.2006.9.115 PubMedCrossRef

34.

World Health Organization (2011) Global Database on Body Mass Index (BMI): BMI Classification. United Nations. http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. Accessed 8 May 2012

35.

Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2011) Unweighted response rates for National Health and Nutrition Examination Survey (NHANES) 2005–2006 by Age and Gender. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/data/nhanes/response_rates_cps/RRT0506MF.pdf. Accessed 8 May 2012

36.

Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2011) Unweighted response rates for National Health and Nutrition Examination Survey (NHANES) 2007–2008 by age and gender. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/data/nhanes/response_rates_cps/RRT0708MF.pdf. Accessed 8 May 2012

37.

Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (1996) Analytic and reporting guidelines: the Third National Health and Nutrition Examination Survey, NHANES III (1988–94). U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/data/nhanes/nhanes3/nh3gui.pdf Accessed 8 Nov 2013

38.

Miller PD (2007) Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 20(3):186–190. doi:10.1111/j.1525-139X.2007.00271.x PubMedCrossRef

39.

Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22(4):503–508. doi:10.1359/jbmr.070112 PubMedCrossRef

40.

Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20(12):2105–2115. doi:10.1359/jbmr.050817 PubMedCrossRef

41.

Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, Eriksen EF, Miller PD (2008) Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 74(5):641–648. doi:10.1038/ki.2008.193 PubMedCrossRef

42.

Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2:138

43.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (113):S1-130. doi:10.1038/ki.2009.188

44.

Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S (2013) Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res 28(10):2049–2059. doi:10.1002/jbmr.2058 PubMedCrossRef

45.

Tanko LB, Qin G, Alexandersen P, Bagger YZ, Christiansen C (2005) Effective doses of ibandronate do not influence the 3 years progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 16(2):184–190. doi:10.1007/s00198-004-1662-x PubMedCrossRef

46.

Hill JA, Goldin JG, Gjertson D, Emerick AM, Greaser LD, Yoon HC, Khorrami S, Aziz D, Adams JS (2002) Progression of coronary artery calcification in patients taking alendronate for osteoporosis. Acad Radiol 9(10):1148–1152PubMedCrossRef

47.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. doi:10.1056/NEJMoa0809493 PubMedCrossRef

48.

Centers for Disease Control and Prevention (2007) Prevalence of chronic kidney disease and associated risk factors—United States, 1999–2004. MMWR Morb Mortal Wkly Rep 56 (8):161–165

49.

Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, Chen SC, Qiu Y, Wang C, Li S, Vassalotti JA, Collins AJ (2008) CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 51(4 Suppl 2):S13–20. doi:10.1053/j.ajkd.2007.12.016 PubMedCrossRef

50.

Zimmerman SI, Girman CJ, Buie VC, Chandler J, Hawkes W, Martin A, Holder L, Hebel JR, Sloane PD, Magaziner J (1999) The prevalence of osteoporosis in nursing home residents. Osteoporos Int 9(2):151–157PubMedCrossRef

51.

Center for Drug Evaluation and Research (CDER) (2010) Guidance for industry: Pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labeling. U.S. Food and Drug Administration, Department of Health and Human Services, Silver Spring, http://www.fda.gov/Drugs/DrugSafety/ucm270199.htm. Accessed 24 May 2013

Title: Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005–2008: Is treatment with bisphosphonates an option?
Authors: R. Lubwama
A. Nguyen
A. Modi
C. Diana
P. D. Miller
Publication date: 01-05-2014
Publisher: Springer London
Published in: Osteoporosis International / Issue 5/2014
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-014-2645-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005–2008: Is treatment with bisphosphonates an option?

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2014

Gender differences in the relationships between lean body mass, fat mass and peak bone mass in young adults

The biomaterial-mediated healing of critical size bone defects in the ovariectomized rat

Refracture of osteoporotic vertebral body concurrent with cement fragmentation at the previously treated vertebral level after balloon kyphoplasty: a case report

Nitric oxide signaling in mechanical adaptation of bone

Causal relationship between the AHSG gene and BMD through fetuin-A and BMI: multiple mediation analysis

Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw